NCT04172233View on ClinicalTrials.gov

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

AK101

AK101 is an anti-IL-12/23p40 monoclonal antibody.

BIOLOGICAL

placebo

matching placebo

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Akeso Tiancheng, Inc

OTHER

lead

Akeso

INDUSTRY